Despite considerable efforts, malaria is still one of the most devastating infectious diseases
in the tropics. The rapid spread of antimalarial drug resistance currently compounds this …

Background There is currently no licensed antiviral drug for treatment of dengue.
Chloroquine (CQ) inhibits the replication of dengue virus (DENV) in vitro. Methods and …

Multidrug resistance has rendered monotherapy for malaria useless in most parts of the
world, and has also compromised the usefulness of many of the available combination …

Although chloroquine-resistance (CQR) in Plasmodium falciparum is increasing and
resistance to other blood schizonticidal anti-malarials has been reported, the molecular …

Background Resistance to cheap effective antimalarial drugs, especially to pyrimethamine-
sulphadoxine (Fansidar), is likely to have a striking impact on childhood mortality in sub …

Abstract Background Chloroquine (CQ), amodiaquine (AQ), and sulfadoxine‐pyrimethamine
(SP) are inexpensive drugs, but treatment failure is a problem. Combination therapy may …

Objectives In the Gambia, chloroquine (CQ) plus sulphadoxine-pyrimethamine (SP) is the
first-line antimalarial treatment. Plasmodium falciparum parasites carrying mutations …

Non-compliance to correct dosing is thought to be one of the main causes of treatment
failure of chloroquine in the home management of childhood malaria. There are few studies …

Resistance to chloroquine (CQ) requires its replacement as first-line therapy for
uncomplicated malaria in much of Africa. Combination therapy may improve efficacy and …

Background. Recent clinical trials in the Lao People's Democratic Republic have
demonstrated that chloroquine and sulfadoxine-pyrimethamine, which are national malaria …